Design of antisense oligonucleotides against twist1 gene and evaluation of their anti-invasive effects in prostate cancer cell lines
Archives of Advances in Biosciences,
Vol. 11 No. 1 (2020),
8 January 2020
Introduction: Prostate cancer is one of the most common cancers and the second major cause of mortality in men. Different researches have shown that the overexpression of a gene called twist1 leads to initiation of metastasis process in this cancer. TWIST1 protein triggers this process through stimulating the transition pathway of cells from epithelial to mesenchymal tissue.
Materials and Methods: In this study, four oligonucleotides of antisense RNA have been designed for twist1 gene, and its anti-metastatic effect was examined in two cell lines PC3 and LNCaP. The antisense oligonucleotides (ASOs) were designed as single strands with a length of 20 nucleotides and chosen from ASOs suggested by Soligo program. The ASOs were synthesized in phosphorothioated form. MTT assay was used for evaluating the ASOs cytotoxicity effect on PC3 and LNCaP cell lines. The cell lines were transfected with 500 nmol of antisense oligonucleotides using cationic polymer turbofect and incubated for 48 hours, and then, their invasive ability were measured by CytoSelect™ Cell Invasion Assay Kit.
Results: The anti-invasive effect of ASOs in LNCaP and PC3 had a significant difference. This effect was more significant in LNCaP cell line as compared to PC3. The most anti- invasive effect was observed in LNCaP cell line (50%).
Conclusion: According to the results, Antisense oligonucleotides were effective in decreasing the invasion ability of two cell lines PC3 and LNCaP and therfore can be considered as a good candidate for preventing the prostate cancer metastasis.
- Prostate cancer
- Antisense oligonucleotides
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal AJCacjfc. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018;68(6):394-424.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DMJIjoc. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. 2010;127(12):2893-917.
Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, et al. Bone metastases: an overview. 2017;11(1).
Gajula RP, Chettiar ST, Williams RD, Nugent K, Kato Y, Wang H, et al. Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells. 2015;17(1):16-31.
Qin Q, Xu Y, He T, Qin C, Xu JJCr. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. 2012;22(1):90.
Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. Twist is a potential oncogene that inhibits apoptosis. 1999;13(17):2207-17.
Kwok WK, Ling M-T, Lee T-W, Lau TC, Zhou C, Zhang X, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. 2005;65(12):5153-62.
Lu S-m, Liang Y, Tian J-j, LI J-f, Wei X, Wang H-bJCmj. Twist modulates lymphangiogenesis and correlates with lymph node metastasis in supraglottic carcinoma. 2011;124(10):1483-7.
Puisieux A, Valsesia-Wittmann S, Ansieau SJBjoc. A twist for survival and cancer progression. 2006;94(1):13.
YANG J, MANI SA, DONAHER JL, RAMASWAMY S, ITZYKSON RA, COME C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. 2007;129(4):43-55.
Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. 2006;12(18):5369-76.
Bakhtiari N, Saadatnia G. RNA based antisense drugs: different types, molecular mechanisms and clinical trials. 2014.
Chan JH, Lim S, Wong WFJC, pharmacology e, physiology. Antisense oligonucleotides: from design to therapeutic application. 2006;33(5‐6):533-40.
Forbes S, Beare D, Bindal N, Bamford S, Ward S. Cole CG et al. COSMIC: High-Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer. 2016.
Tamm I, Dörken B, Hartmann GJTL. Antisense therapy in oncology: new hope for an old idea? 2001;358(9280):489-97.
Dias N, Stein CJMct. Antisense oligonucleotides: basic concepts and mechanisms. 2002;1(5):347-55.
Orr RJCoimt. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. 2001;3(3):288-94.
Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. 2010;375(9719):998-1006.
Wan WB, Migawa MT, Vasquez G, Murray HM, Nichols JG, Gaus H, et al. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. 2014;42(22):13456-68.
Oba M, Tanaka MJB, Bulletin P. Intracellular internalization mechanism of protein transfection reagents. 2012;35(7):1064-8.
Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, de Menezes DEL, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. 2001;7(12):3920-7.
Gleave M, Miyake HJWjou. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen-and chemo-sensitivity in prostate cancer. 2005;23(1):38-46.
Li W-C, Ye S-L, Sun R-X, Liu Y-K, Tang Z-Y, Kim Y, et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. 2006;12(23):7140-8.
Khatib A-M, Fallavollita L, Wancewicz EV, Monia BP, Brodt PJCR. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. 2002;62(19):5393-8.
Margheri F, D'alessio S, Serrati S, Pucci M, Annunziato F, Cosmi L, et al. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. 2005;12(8):702.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times